^
    4d
    STELLAR-002: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FH (Fumarate Hydratase)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • zanzalintinib (XL092)
    4d
    CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=27, Completed, Jose Lutzky, MD | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    11d
    A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    12d
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    17d
    Abscopal Effect Induced by LAG-3/PD-1 Inhibition and Radiation Therapy in Metastatic Acral Melanoma: A Case Report. (PubMed, Case Rep Oncol)
    Relatlimab, a LAG-3 inhibitor, in combination with nivolumab, a PD-1 inhibitor, has recently emerged as a dual ICI strategy targeting T-cell exhaustion. This case illustrates the potential synergistic effect of sequential LAG-3/PD-1 inhibition followed by radiation therapy in eliciting systemic immune activation in AM. It represents the first reported instance of an abscopal effect associated with relatlimab-based immunotherapy, suggesting that strategic sequencing of immunotherapy and radiation may be critical in overcoming immune resistance in this challenging melanoma subtype.
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    19d
    NOBLE: Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, National Health Research Institutes, Taiwan
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • cisplatin • gemcitabine • relatlimab (BMS-986016)
    20d
    Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in cancer patients. (PubMed, J Cardiovasc Pharmacol)
    HFCs were exposed for 48h to Nivolumab plus Relatlimab, Ipilimumab, or Atezolizumab, either alone or in triplet combinations. Our findings demonstrate that ICI triplets elicit potent immune activation against cardiomyocytes, providing the first preclinical evidence of direct cardiotoxic potential in this setting. These results highlight the need for enhanced clinical surveillance and cardio-oncology monitoring in patients receiving triple ICI combinations, as these regimens expand in clinical practice.
    Journal • Checkpoint inhibition
    |
    GZMB (Granzyme B) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1m
    RELATIVITY-106: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=83, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=162 --> 83 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • relatlimab (BMS-986016)
    1m
    GIANT: Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (clinicaltrials.gov)
    P2, N=92, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1m
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov)
    P2, N=20, Completed, Dan Zandberg | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1m
    RELATIVITY-073: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (clinicaltrials.gov)
    P2, N=266, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1m
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (clinicaltrials.gov)
    P2, N=90, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2027 --> Nov 2028 | Trial primary completion date: Jul 2027 --> Nov 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    LDH elevation
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)